% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Louis:129085,
      author       = {D. N. Louis and A. Perry and G. Reifenberger$^*$ and A. von
                      Deimling$^*$ and D. Figarella-Branger and W. K. Cavenee and
                      H. Ohgaki and O. Wiestler$^*$ and P. Kleihues and D. W.
                      Ellison},
      title        = {{T}he 2016 {W}orld {H}ealth {O}rganization {C}lassification
                      of {T}umors of the {C}entral {N}ervous {S}ystem: a summary.},
      journal      = {Acta neuropathologica},
      volume       = {131},
      number       = {6},
      issn         = {1432-0533},
      address      = {Berlin},
      publisher    = {Springer},
      reportid     = {DKFZ-2017-05090},
      pages        = {803 - 820},
      year         = {2016},
      abstract     = {The 2016 World Health Organization Classification of Tumors
                      of the Central Nervous System is both a conceptual and
                      practical advance over its 2007 predecessor. For the first
                      time, the WHO classification of CNS tumors uses molecular
                      parameters in addition to histology to define many tumor
                      entities, thus formulating a concept for how CNS tumor
                      diagnoses should be structured in the molecular era. As
                      such, the 2016 CNS WHO presents major restructuring of the
                      diffuse gliomas, medulloblastomas and other embryonal
                      tumors, and incorporates new entities that are defined by
                      both histology and molecular features, including
                      glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant;
                      diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive
                      ependymoma; medulloblastoma, WNT-activated and
                      medulloblastoma, SHH-activated; and embryonal tumour with
                      multilayered rosettes, C19MC-altered. The 2016 edition has
                      added newly recognized neoplasms, and has deleted some
                      entities, variants and patterns that no longer have
                      diagnostic and/or biological relevance. Other notable
                      changes include the addition of brain invasion as a
                      criterion for atypical meningioma and the introduction of a
                      soft tissue-type grading system for the now combined entity
                      of solitary fibrous tumor / hemangiopericytoma-a departure
                      from the manner by which other CNS tumors are graded.
                      Overall, it is hoped that the 2016 CNS WHO will facilitate
                      clinical, experimental and epidemiological studies that will
                      lead to improvements in the lives of patients with brain
                      tumors.},
      cin          = {G380 / M010 / L401 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)G380-20160331 / I:(DE-He78)M010-20160331 /
                      I:(DE-He78)L401-20160331 / I:(DE-He78)L101-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27157931},
      doi          = {10.1007/s00401-016-1545-1},
      url          = {https://inrepo02.dkfz.de/record/129085},
}